List view / Grid view
Thermo Fisher Scientific Inc., the world leader in serving science, today introduced new capabilities for laboratories performing a wide range of qualitative and quantitative proteomics workflows.
16 February 2011 | By Hubert Hondermarck, Professor and head of U908 INSERM research unit – Growth factor signalling in breast cancer – functional proteomics, University of Lille
The recent progresses in the field of proteomics now enable large scale, high throughput, sensitive and quantitative protein analysis. Therefore, applying proteomics in clinical oncology becomes realistic. From the analysis of cell cultures to biological fluids and tumour biopsies, proteomic investigations of cancers are flourishing and new candidate biomarkers and…
16 December 2010 | By Carl A.K. Borrebaeck and Christer Wingren, Department of Immunotechnology and CREATE Health, Lund University
Deciphering crude proteomes in the quest for candidate biomarker signatures for disease diagnostics, prognostics and classifications has proven to be challenging using conventional proteomic technologies. In this context, affinity protein microarrays, and in particular recombinant antibody microarrays, have recently been established as a promising approach within high-throughput (disease) proteomics1-3. The…
29 October 2010 | By Brian Flatley Dept of Chemistry, University of Reading, Reading and Harold Hopkins Dept of Urology, Royal Berkshire NHS Foundation Trust Hospital, Reading and Peter Malone Harold Hopkins Dept of Urology, Royal Berkshire NHS Foundation Trust Hospital, Reading and Rainer Cramer Dept of Chemistry, University of Reading, Reading
Each year, approximately 10,000 men in the UK die as a result of prostate cancer (PCa) making it the third most common cancer behind lung and breast cancer. Worldwide, more than 670,000 men are diagnosed every year with the disease. Current methods of diagnosis of PCa mainly rely on the…
Thermo Fisher Scientific Inc., the world leader in serving science, and Proteome Sciences plc (LSE: PRM), a leading provider of protein biomarker services, today announced the companies will collaborate to deliver innovative products for protein biomarker research.
Thermo Fisher Scientific Inc., the world leader in serving science, today announced a new application note entitled “Enhancing Phosphotyrosine Proteome Coverage using a Combined ETD and CID Approach on a LTQ Orbitrap XL ETD”.
Innovative drug delivery technologies are key components of drug development, with commercial and intellectual values. PEGylation is an excellent example of a delivery system that has scientific and multi-billion dollar commercial importance due to the remarkable improvement in the circulatory half lives of therapeutics, especially for proteins and peptides but…
29 May 2009 | By
The pharmaceutical industry continues to experience a high attrition rate during the latter stages of small molecule therapeutic development, most disappointingly during the late, and highly expensive stages of Phase II and Phase III trial1. If left unchecked, it is likely that this late-stage failure in drug development will only…
7 February 2009 | By Dr Chris Taylor, Senior Software Engineer, European Bioinformatics Institute and Lennart Martens, Group Co-ordinator of Proteomics Services, European Bioinformatics Institute
There are compelling reasons for regularising the capture and description of proteomics data. Adhering to community-consensus specifications for the annotation of data sets can increase confidence in results and the conclusions drawn upon them, and supports data re-use; working with standard formats and vocabularies can raise efficiency and facilitates sophisticated…
10 January 2009 | By
The awarding of the Nobel Prize in chemistry to Fenn, Tanaka, and Wüthrich for their work on methods for the identification and structural characterisation of biomolecules has heralded the increasing importance of proteomics in biomedical and fundamental research. Today, vendors offer a variety of mass spectrometric instruments to provide a…
3 December 2008 | By
In its Research Framework Programme 7 (2007-2013), the European Commission sets the focus in health research on bringing the huge high-throughput data collection efforts of earlier programmes to the systems level. The ultimate goal of systems biology is the integration of various types of experimental data into models that represent…
29 September 2008 | By
Advances in proteomics have constantly altered our understanding of cell biology and biochemistry by providing new approaches and techniques to identify complex proteomes, protein-protein interactions and post-translational modifications. Additionally, proteomic approaches are believed to have enormous potential for discovery of disease biomarkers that can provide diagnostic, prognostic and therapeutic targets…
2 August 2008 | By
The 7th World Congress of the Human Proteome Organisation, HUPO, will be held at the RAI Congress Centre in Amsterdam, the Netherlands, from 16-20 August 2008.
2 August 2008 | By
Stem cells have two important characteristics that distinguish them from other cells: the ability to self-renew through cell division for a prolonged period, and to differentiate into multiple cells with specialised functions. The power of stem cells for tissue development, regeneration and renewal has been well known to embryologists for…
19 July 2008 | By
MALDI FT-ICR MS platform for proteomics: Rationale for an offline approach and optimised implementation A number of sophisticated approaches have been developed to study the structure and function of genes, including the whole-scale sequencing of entire organisms[1], global transcriptional profiling[2], and forward genetic studies[3]. However, these techniques are ultimately limited…
